Pilot study of the combination of sorafenib and fractionated irinotecan in pediatric relapse/refractory hepatic cancer
Not Applicable
- Conditions
- hepatoblastoma and hepatocellular carcinoma of children
- Registration Number
- JPRN-UMIN000022324
- Lead Sponsor
- Kanagawa Children's Medical Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 12
Inclusion Criteria
Not provided
Exclusion Criteria
1. active infectious disease 2. congenital or acquired immunodeficiency 3. inadequate case by physician's judgement
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method